TrialESMO open2021

Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.

E Van Cutsem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.